The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirus infections, the development and attributes of SIGA Technologies, Inc. (“SIGA”) products, and the future operations, opportunities or financial performance of SIGA. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimations based upon the information available to SIGA as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements.

Undue reliance should not be placed on forward looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.

For a more detailed discussion of our risks, see the Risk Factors section in SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC and our other filings with the SEC, including our most recent Quarterly Report, all of which are available on our website, www.siga.com.
TPOXX: The Power of Public Private Partnerships

Public
- Ensuring the development and stockpile of MCMs

Private
- Investing in capabilities to create value for stakeholders

Partnership
- Opportunities / Challenges
TPOXX: Developing and Stockpiling a Smallpox Antiviral Drug
Smallpox: A Deadly Killer

- Smallpox has a **potential 30% fatality rate** and was responsible for approximately **300 million deaths** worldwide in the 20th century.

- Smallpox is a **highly contagious** virus:
  - Spreads person-to-person
  - Can be transmitted through speaking, breathing, or touching
  - Can be transmitted by direct contact with infected fluids and contaminated objects
  - It is estimated that each person infected with smallpox would infect 5-7 other people if not vaccinated/treated

- Successful eradication resulted from coordinated global vaccination campaigns.

- Current smallpox vaccine and other vaccinia-based vaccines may cause serious adverse reactions, especially in individuals who are very young or very old, or immunocompromised (e.g., those with eczema or atopic dermatitis).
TPOXX (tecovirimat) Mechanism of Action

- Smallpox spreads by developing a secondary envelope
- This allows the virus to leave the cell and enter the bloodstream
- TPOXX’s mechanism of action inhibits maturation, preventing release and spread of viral particles to other cells

TPOXX Inhibits the viral envelope formation and spread of the virus

IMV: Intracellular Immature Virus
IEV: Intracellular Enveloped Virus
EEV: Extracellular Enveloped Virus

TPOXX Development History

TPOXX (ST-246) Lead

2003

NIH SBIR1

NIH SBIR2

NIH SBIR2c

DMID/NIH dev

NIH/BARDA dev

BARDA Advanced Development & Acquisition

CDC/FDA

DTRA/USAMRIID

NDA Submitted

NDA Approved July 13

2018
Efficacy Data in NHPs and Rabbits (NEJM)

A. Dose Exploration in Nonhuman Primates

- Placebo (N=6)
- 10 mg/kg (N=5)
- 3 mg/kg (N=5)
- 1 mg/kg (N=5)
- 0.3 mg/kg (N=5)

B. Dose Exploration and Pharmacokinetics in Nonhuman Primates

- Placebo (N=6)
- 20 mg/kg (N=6)
- 10 mg/kg (N=6)
- 3 mg/kg (N=6)

C. Dose Exploration in Rabbits

- Placebo (N=10)
- 120 mg/kg (N=10)
- 80 mg/kg (N=10)
- 40 mg/kg (N=10)
- 20 mg/kg (N=10)

D. Dose Exploration and Pharmacokinetics in Rabbits

- 120 mg/kg (N=8)
- 80 mg/kg (N=8)
- 40 mg/kg (N=8)

Grosenbach, et. al., NEJM, 2018;379:44-53.
Pharmacokinetics in NHPs and Humans (NEJM)

TPOXX: Investing in Capabilities to Create Value for Stakeholders
MISSION
A commercial-stage pharmaceutical company focused on the health security market

VALUABLE THERAPEUTIC PORTFOLIO

*TPOXX® (tecovirimat)*
- Oral capsule smallpox antiviral
  - FDA Licensure in July, 2018
  - U.S. Government contracts worth a total of >$1 billion awarded (if all options are exercised)
- IV formulation smallpox antiviral
  - Phase 1a study completed; Phase 1b study commenced in third quarter 2018; expect to complete 2019
  - Up to 212,000 courses of IV TPOXX to be procured under 2018 U.S. Government contract (if all options are exercised)
  - Development is being funded by U.S. Government

2nd Mechanism of Action Smallpox Antiviral
Preclinical: efficacy shown in animal model
U.S. Government Investment in Biodefense has Enabled SIGA to Build a Robust Capability for Drug Development and Commercialization

End-to-end network of proven partners established

- Over 20 partnered companies
- TPOXX developed from lead identification through commercial supply chain
- U.S. based supply chain for robust product supply to customers
- Experienced oversight of network by SIGA leadership
- Proven capabilities that can be scaled for future products

Network design minimizes fixed costs and provides ability to scale to product development and procurement demands.
2018 BARDA Contract: Potential Path for Procurement Revenue

Maintaining the US Stockpile of 1.7 million courses of TPOXX

<table>
<thead>
<tr>
<th>Previous Contract Timeline (no options)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>New Contract Potential Timeline with Options (7-year shelf life)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018  2019  2020  2021  2022  2023  2024</td>
</tr>
</tbody>
</table>

7-year shelf life

<table>
<thead>
<tr>
<th>Procurement Revenues (if all options are exercised)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Procurement</td>
</tr>
<tr>
<td>IV Procurement</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>
Priority Review Voucher

- 21st Century Cures Act of 2016 created Priority Review Voucher (PRV) eligibility for Medical Countermeasures to material threats as determined by the U.S. Government
- Legislation provides the sponsor of a qualifying product with a PRV to receive priority review for a future drug of their choice, resulting in an accelerated review
- PRV may be sold commercially without restriction
- Smallpox is on the list of Material Threats, and TPOXX is a novel treatment for smallpox

Priority Review Vouchers make investment more appealing through secondary market

SIGA received the first MCM PRV with the FDA approval of TPOXX on July 13, 2018

1U.S. House of Representatives Amendment to the Senate Amendment to H.R.34.Subtitle H – Medical Countermeasures Innovation. Available at: http://docs.house.gov/billsthisweek/20161128/CPRT-114-HPRT-RU00-SAHR34.pdf.
Biodefense is an Attractive Specialty Market...

**MARKET INCENTIVES**

- **R&D**: Government provides majority of R&D funding
- **Limited Buyers with Pre-Defined Volume**: Procurement contracts typically awarded multiple years prior to anticipated NDA, providing early cash flow
- **Priority Review Voucher**: Potential eligibility upon NDA approval, lucrative secondary market
- **Technology / Capability Platform Building**: Opportunity to build technology and expertise in product fields
- **Capital Investment**: In specialized products, shared capital investments have been made to build infrastructure for supply chain and/or R&D

...that strategically overlaps with broader infectious disease markets.

Compassionate Use in Treatment of Vaccinia Complications

2007

• **28-month old child**
  Diagnosed with eczema vaccinatum after contact with his father, an active U.S. military service member who had recently received smallpox vaccination

2009

• **20-year old active U.S. military service member**
  Presented with progressive vaccinia after receiving smallpox vaccination

• **35-year old female**
  Developed a vaccinia infection after exposure to a recombinant vaccinia-based rabies vaccine

2011

• **25-year old female**
  Developed a vaccinia infection after changing a bandage covering a smallpox vaccination site for her boyfriend, a U.S. military contractor

2015

• **Active U.S. military male service member**
  Developed vaccine complications due to a concomitant undiagnosed cancer

Vaccinia virus has long been examined as a vector for potential treatment of cancer, either as an oncolytic virus or a delivery vehicle for cancer antigens.

No oncology product has been licensed using vaccinia, and many products have failed.

A recent search in 2018 of clinicaltrial.gov shows over 50 vaccinia clinical trials in oncology.

A new generation of replicating vectors are advancing in development.

TPOXX could potentially enable higher dosing or higher replication competence vaccinia vectors.

SIGA is pursuing potential collaborations with multiple oncology companies to evaluate use of TPOXX as a rescue therapy or co-therapy for delivery of vaccinia vectors to cancer patients.

Partnerships: Opportunities and Challenges
BARDA SIGA Public-Private Partnership

<table>
<thead>
<tr>
<th>Challenge</th>
<th>Opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lots of stakeholders</td>
<td>Access to leading experts</td>
</tr>
<tr>
<td>Compliance is complex</td>
<td>Only the determined overcome the barriers to entry</td>
</tr>
<tr>
<td>Monopsony with market uncertainty</td>
<td>Limited sales/marketing organization required</td>
</tr>
<tr>
<td>Development &amp; Procurement cycles long, with potential gaps</td>
<td>Majority of R&amp;D funded, procurement cycles improving</td>
</tr>
<tr>
<td>Opaque requirements process</td>
<td>Potential stockpile purchase prior to FDA licensure</td>
</tr>
</tbody>
</table>
Organizational Keys to Success

- Excel at collaboration
- Use data to drive decisions
- Deliver on commitments
- Seek creative solutions
- Build a culture of compliance
- Listen to the customer, know when to be patient
- Engage in the MCM enterprise
Acknowledgements

- SIGA Research & Development Team
- BARDA
- NIAID
- FDA
- CDC
- WHO
- DTRA
- OBRA
- USAMRIID
- CROs & CMOs
- Pox colleagues